Inhibrx CRC Data Update Reinforces Pipeline Narrative, Leaves Core BLA Risks Unchanged

What happened

Inhibrx announced updated interim data for ozekibart in late-line colorectal cancer, continuing to show a signal of activity in heavily pretreated patients as of an April 2026 cutoff. This aligns with prior reports of high disease control rates in the CRC expansion cohort, supporting the label expansion narrative. However, the release is promotional and lacks specifics on durability or safety, failing to address the critical hepatotoxicity risks documented in filings. The primary investment driver remains the BLA submission for chondrosarcoma by Q2 2026, which this update does not impact directly. Consequently, the news serves as incremental validation but does not shift the near-term regulatory or safety overhangs.

Implication

The CRC data reinforces the bull case by demonstrating ongoing activity in a challenging indication, potentially enhancing long-term value if the BLA succeeds. Yet, it ignores the binding constraint of hepatotoxicity, where past fatal events and higher AE rates versus placebo could trigger FDA scrutiny and delays. Financially, the company's cash burn and pre-commercialization spend continue unabated, with no revenue offset from this interim update. Market sentiment remains crowded on the single BLA catalyst, so this news is unlikely to drive a re-rating without clearer de-risking of regulatory pathways. Investors should therefore maintain caution, focusing on concrete BLA readiness signals over expansion cohort updates that lack maturity.

Thesis delta

The core investment thesis of a WAIT rating, centered on a near-term BLA submission with asymmetric downside risk, remains unchanged. This update slightly increases the probability of the bull scenario by strengthening the CRC expansion narrative, but it does not alter the fundamental risks of hepatotoxicity or timeline execution that dominate the valuation framework.